Latest experts appointed to join 成人VR视频鈥檚 Scientific Advisory Committee
Share
成人VR视频 has appointed eight new experts to its 鈥Scientific Advisory Committee鈥(SAC), an external expert group which provides guidance and recommendations to 成人VR视频 on R&D programmes and broader outbreak response efforts.
The new members' scientific input, guidance and challenge will be critical in the continued implementation of the 成人VR视频 2.0 strategy, which aims to accelerate the development of vaccines and other biological countermeasures to tackle emerging infectious diseases and enhance global preparedness for future epidemic and pandemic threats.
As the global landscape of vaccine development and manufacturing continues to evolve at pace, in March 2024 成人VR视频 鈥launched a recruitment drive 鈥痵eeking additional experts and global health professionals with extensive experience across relevant scientific and product development disciplines to join its SAC.
Eight new experts have been selected to join the SAC through a rigorous review process of candidates based on expertise, experience, and geographical representation. The appointments were approved by the 成人VR视频 Board in May 2024.
The new SAC members are:
- Associate Professor Ifedayo Adetifa, Independent Public Health Expert, Nigeria
- Dr Paula Goldin, Senior Medical Director PPD, Thermo Fisher, Argentina
- Dr Beth-Ann Griswold Coller, Consultant, BCG Vaccine Consulting LLC, USA
- Professor Kevin Kee-Jong Hong, Korea mRNA Vaccine Initiative, Korea
- Dr Luciana C. C. Leite, Head of Recombinant BCG Laboratory, Instituto Butantan, Brazil,
- Dr Placide Mbala-Kingebeni, Head of Epidemiology and Global Health Department, Institut National de Recherche Biomedicale, Democratic Republic of Congo
- Mr Sly Ngoni Mutyavaviri, Senior GMP Inspector, Medicines Control Authority of Zimbabwe and SADC Medicines Regulatory Harmonisation Inspections Coordinator, SADC Medicines Regulatory Harmonisation, Zimbabwe
- Dr Andre Siqueira, Public Health Researcher, Funda莽茫o Oswaldo Cruz (Fiocruz), Brazil
As the Chair of 成人VR视频鈥檚 Scientific Advisory Committee, I am delighted to welcome these new members to our team. Expanding our collective expertise is crucial, given the rapidly changing vaccine development and manufacturing landscape, and ongoing threats of a future pandemic. I鈥檝e no doubt that 成人VR视频 will greatly benefit from the fresh perspectives and extensive experience that our new appointees bring alongside that of our existing member.
The work we do at 成人VR视频 depends entirely on the quality of our scientific understanding and our ability to keep track of the rapid advances in the biology and technology of vaccine development. As we near the mid-way point of 成人VR视频 2.0, the guidance and insights provided by our Scientific Advisory Committee (SAC) have been and will continue to be crucial to advancing our work and tackling the challenge of emerging infectious diseases. We are delighted to welcome both the SAC鈥檚 returning and new members. These newest members extend the SAC鈥檚 global representation and expertise and we are thrilled to have them join our efforts to build a pandemic-free future.
SAC members terms last for three years and are renewable. Twenty-seven current members of the SAC will continue in their roles. These members are:
- Professor Alash'le Abimiku鈥- International Research Center of Excellence, Institute of Human Virology, Nigeria
- Dr Vincent Ahonkhai - Gwynedd Consultancy Group, LLC, USA
- Emeritus Professor Vineeta Bal鈥- Indian Institute of Science Education and Research, Pune, India
- Dr Rick A. Bright - Bright Global Health, USA
- Dr Paula Bryant鈥- National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
- Assistant Professor Yunlong Cao - Peking University, China
- Dr Peter Dull鈥- Bill & Melinda Gates Foundation, USA
- Professor Azra Ghani鈥- Imperial College London, United Kingdom
- Mrs Rebecca Grais鈥 Pasteur Network, France
- Professor Glenda E. Gray - South African Medical Research Council, South Africa
- Dr Ana Maria Henao-Restrepo 鈥 World Health Organization, Switzerland
- Dr Emmanuel Hanon鈥(Chair) - Vicebio, Belgium
- Professor Ken J. Ishii鈥- International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Japan
- Professor Amine Kamen - McGill University, Canada
- Professor Michael King (Vice Chair)鈥 University of Virginia, USA
- Dr Gary Kobinger 鈥 Galveston National Laboratory/Institute for Drug Discovery, University of Texas Medical Branch, USA
- Dr Phil Krause鈥 World Health Organization, USA
- Professor Marc Lipsitch鈥 Harvard T.H. Chan School of Public Health, USA
- Mr Dominique Maugeais鈥 RH Solutions, France
- Dr Laura Palomares Aguilera (Vice Chair)鈥- Instituto de Biotecnolog铆a, Universidad Nacional Aut贸noma de M茅xico (UNAM), Mexico
- Dr Peter Paradiso鈥- Paradiso Biologics Consulting, LLC, USA
- Professor Stanley Plotkin鈥- University of Pennsylvania, USA
- Dr Marie-Jos茅 Quentin-Millet - MJQuentinMillet Consulting, France
- Professor Rino Rappuoli鈥- Fondazione Biotecnopolo di Siena, Italy
- Lynda Stuart - Institute for Protein Design, USA
- Professor Linfa Wang鈥- Duke-NUS Medical School, Singapore
- Professor George Warimwe - KEMRI-Wellcome Trust Research Programme, Kenya and University of Oxford, United Kingdom
Richard Hatchett reflects on a 鈥渂anner year for viruses鈥 and looks ahead to 2025
Valneva expands access to Asia for its chikungunya vaccine with Serum
